Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
IFxHu-20 by TuHURA Biosciences for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
IFxHu-20 is under clinical development by TuHURA Biosciences and currently in Phase I for Cutaneous Squamous Cell Carcinoma (cSCC). According...